AnaptysBio Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Rati Pinhe, Priyanka Grover and Joy Shao.
Our next presenting company is AnaptysBio and presenting on behalf of the company, we have CEO, Dan Faga. Dan?
Hello, everyone. Thank you for having me join today, Anupam. These are our forward-looking statements. This is going to be a transformational year for Anaptys. In September, we announced -- September 2025, we announced the intention to separate into two businesses through the course of this year, and that is likely to happen in the second quarter at this point.
The 2 businesses are generically referred to as Biopharma Co and Royalty Management Co at this time.
Biopharma Co will be anchored by three clinical assets. The operating business will be driven through ANB033. We are enrolling
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
